PMID- 24624086
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140624
LR  - 20211021
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 5
DP  - 2014
TI  - Calcium dysregulation in atrial fibrillation: the role of CaMKII.
PG  - 30
LID - 10.3389/fphar.2014.00030 [doi]
LID - 30
AB  - Atrial fibrillation (AF) is the most frequently encountered clinical arrhythmia 
      and is associated with increased morbidity and mortality. Ectopic activity and 
      reentry are considered major arrhythmogenic mechanisms contributing to the 
      initiation and maintenance of AF. In addition, AF is self-reinforcing through 
      progressive electrical and structural remodeling which stabilize the arrhythmia 
      and make it more difficult to treat. Recent research has suggested an important 
      role for Ca(2+)-dysregulation in AF. Ca(2+)-handling abnormalities may promote 
      ectopic activity, conduction abnormalities facilitating reentry, and AF-related 
      remodeling. In this review article, we summarize the Ca(2+)-handling derangements 
      occurring in AF and discuss their impact on fundamental arrhythmogenic 
      mechanisms. We focus in particular on the role of the multifunctional 
      Ca(2+)/calmodulin-dependent protein kinase type-II (CaMKII), which acts as a 
      major link between Ca(2+)-dysregulation and arrhythmogenesis. CaMKII expression 
      and activity are increased in AF and promote arrhythmogenesis through 
      phosphorylation of various targets involved in cardiac electrophysiology and 
      excitation-contraction coupling. We discuss the implications for potential novel 
      therapeutic strategies for AF based on CaMKII and Ca(2+)-handling abnormalities.
FAU - Heijman, Jordi
AU  - Heijman J
AD  - Institute of Pharmacology, Faculty of Medicine, University Duisburg-Essen Essen, 
      Germany.
FAU - Voigt, Niels
AU  - Voigt N
AD  - Institute of Pharmacology, Faculty of Medicine, University Duisburg-Essen Essen, 
      Germany.
FAU - Wehrens, Xander H T
AU  - Wehrens XH
AD  - Cardiovascular Research Institute, Departments of Molecular Physiology and 
      Biophysics, and Medicine-Cardiology, Baylor College of Medicine Houston, TX, USA.
FAU - Dobrev, Dobromir
AU  - Dobrev D
AD  - Institute of Pharmacology, Faculty of Medicine, University Duisburg-Essen Essen, 
      Germany.
LA  - eng
GR  - R01 HL089598/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20140304
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC3940963
OTO - NOTNLM
OT  - CaMKII
OT  - atrial fibrillation
OT  - calcium
OT  - ectopic activity
OT  - reentry
EDAT- 2014/03/14 06:00
MHDA- 2014/03/14 06:01
PMCR- 2014/03/04
CRDT- 2014/03/14 06:00
PHST- 2014/01/21 00:00 [received]
PHST- 2014/02/15 00:00 [accepted]
PHST- 2014/03/14 06:00 [entrez]
PHST- 2014/03/14 06:00 [pubmed]
PHST- 2014/03/14 06:01 [medline]
PHST- 2014/03/04 00:00 [pmc-release]
AID - 10.3389/fphar.2014.00030 [doi]
PST - epublish
SO  - Front Pharmacol. 2014 Mar 4;5:30. doi: 10.3389/fphar.2014.00030. eCollection 
      2014.